1. Management of toxicities of immune checkpoint inhibitors. (March 2016) Authors: Spain, Lavinia; Diem, Stefan; Larkin, James Journal: Cancer treatment reviews Issue: Volume 44(2016) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Issue 3 (4th March 2017) Authors: Bracarda, Sergio; Negrier, Sylvie; Casper, Jochen; Porta, Camillo; Schmidinger, Manuela; Larkin, James; Gross Goupil, Marine; Escudier, Bernard Journal: Expert review of anticancer therapy Issue: Volume 17:Issue 3(2017) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. (2nd May 2016) Authors: Spain, Lavinia; Julve, Maximilian; Larkin, James Journal: Expert opinion on pharmacotherapy Issue: Volume 17:Number 7(2016) Page Start: 1031 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2019) Authors: Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Lesimple, Thierry; Plummer, Ruth; Schachter, Jacob; Dasgupta, Kohinoor; Manson, S... Journal: Lancet oncology Issue: Volume 20:Issue 5(2019) Page Start: 701 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib. (July 2019) Authors: Lewis, Karl; Hauschild, Axel; Larkin, James; Ribas, Antoni; Flaherty, Keith T.; McArthur, Grant A.; Dréno, Brigitte; McKenna, Edward; Zhu, Qian; Mun, Yong; Ascierto, Paolo A. Journal: European journal of cancer Issue: Volume 116(2019) Page Start: 45 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (July 2019) Authors: Eggermont, Alexander M.M.; Blank, Christian U.; Mandala, Mario; Long, Georgina V.; Atkinson, Victoria G.; Dalle, Stéphane; Haydon, Andrew; Lichinitser, Mikhail; Khattak, Adnan; Carlino, Matteo S.; Sandhu, Shahneen; Larkin, James; Puig, Susana; Ascierto, Paolo A.; Rutkowski, Piotr; Schadendorf, Di... Journal: European journal of cancer Issue: Volume 116(2019) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Issue 7 (July 2019) Authors: Andrews, Miles C; Berry, Donald A; Block, Matthew S; Boland, Genevieve M; Bollin, Kathryn B; Carlino, Matteo S; Carvajal, Richard D; Cohen, Jonathan; Davar, Diwakar; Delman, Keith A; Dummer, Reinhard; Farwell, Michael D; Fisher, David E; Fusi, Alberto; Glitza, Isabella C; de Gruijl, Tanja D; Gyor... Journal: Lancet oncology Issue: Volume 20:Issue 7(2019) Page Start: e378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Issue 8 (August 2019) Authors: Long, Georgina V; Dummer, Reinhard; Hamid, Omid; Gajewski, Thomas F; Caglevic, Christian; Dalle, Stephane; Arance, Ana; Carlino, Matteo S; Grob, Jean-Jacques; Kim, Tae Min; Demidov, Lev; Robert, Caroline; Larkin, James; Anderson, James R; Maleski, Janet; Jones, Mark; Diede, Scott J; Mitchell, Tara C Journal: Lancet oncology Issue: Volume 20:Issue 8(2019) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Immune checkpoint inhibitors and cardiovascular toxicity. Issue 9 (September 2018) Authors: Lyon, Alexander R; Yousaf, Nadia; Battisti, Nicolò M L; Moslehi, Javid; Larkin, James Journal: Lancet oncology Issue: Volume 19:Issue 9(2018) Page Start: e447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Issue 11 (November 2018) Authors: Hodi, Frank Stephen; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean-Jacques; Rutkowski, Piotr; Cowey, Charles Lance; Lao, Christopher D; Schadendorf, Dirk; Wagstaff, John; Dummer, Reinhard; Ferrucci, Pier Francesco; Smylie, Michael; Hill, Andrew; Hogg, David; Marquez-Rodas, Ivan; Jiang, Joel;... Journal: Lancet oncology Issue: Volume 19:Issue 11(2018) Page Start: 1480 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗